Answer
Co-administration of rifampicin decreased exposure to linagliptin, a component of Glyxambi, by 40%, suggesting reduced linagliptin efficacy with strong P-gp or CYP3A4 inducers, particularly during long-term use.
Sources for this answer
- Glyxambi 10 mg/5 mg film-coated tablets and Glyxambi 25 mg/5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked